Specialist preclinical contract research organisation (CRO) Cellomatics Biosciences has heralded the start of its next successful phase with four promotions and eight new arrivals. Dr Shailendra Singh, CEO of Cellomatics Biosciences, comments: “Capitalising on our existing strengths and internal team expertise, we intend to further consolidate our position as a specialist biology CRO by broadening and deepening our service offerings in 2024. With these new appointments and internal restructuring, we are poised to catapult ourselves to the next phase of our growth journey.” Cellomatics is…

Check out the Bristows Biotech Review of the Year. This report reflects on the key developments in the biotech industry, including: Legal updates Generative AI  The Unified Patent Court CRISPR technology  Predictions for 2024   READ NOW    

Creative Places enters new era with the appointment of new partner and the retirement of co-founder   Seb Denby is promoted to Partner as co-founder Jonathan Burroughs retires   16th January 2024: Creative Places, a leading R&D real estate advisor, announces the promotion of Seb Denby to Partner and the retirement of its co-founder and former CEO, Jonathan Burroughs.   Based in Cambridge, Creative Places’ award-winning team excels in advising clients on how to develop and invest in locations that can become ‘value add’ places to all that use them.   The strategic…

Sandwich, Kent, UK, 17th January 2023 / Sciad Newswire / Discovery Park Ventures (DPV) announces an investment of £100K into Vox Imaging Technology Ltd. (VIT), an ambitious ophthalmic technology company looking to transform eye imaging in preclinical research and improve drug discovery and development. Its compact and customisable instrument is believed to be the first scanning laser ophthalmoscope especially designed for laboratory use, able to produce high-quality data rapidly. Vox Imaging is the eighth investment from DPV’s first fund. Prevalence of diseases of the eye (such as age-…

As the life sciences sector continues to evolve at a rapid pace, Biocair, a leading global life science logistics expert, stands at the forefront of industry excellence and customer service. Manish Joshi, Biocair’s Chief Commercial Officer, gives us insight into how Biocair is staying ahead of trends that will shape the industry in 2024. Sustainability revolutionizing the life sciences supply chain In the fiercely competitive life science sector, sustainability has emerged as a force reshaping supply chain dynamics. This paradigm shift aligns with a broader industry trend, as indicated by the…

Enter our competition for a chance to win a place on a concentrated three-day bootcamp in Boston with boardroom-style sessions, led by top life science businesses in the Greater Boston cluster, aimed at providing a focused ‘Getting US-ready’ experience. Whether you are looking to enter the US market for investment, collaborations or clients, this is a brilliant opportunity to embark on a journey to elevate your business to the next level. See full details, including eligibility and how to enter         

CELLBANKER® freezing media from AMSBIO is now available in customizable formats, seamlessly integrating into cell manufacturing processes with personalized formulations, volumes, and packaging. Cited in over 500 scientific publications, the CELLBANKER range has proven itself as a safe and reliable solution for storing cells and tissues. This includes GMP-grade, chemically defined formulations specifically designed for the storage of biospecimens for clinical applications. Widespread adoption of cell and gene therapies has required new advances in cell manufacturing and processing to produce…

• Sentiment among UK CFOs has risen for the second consecutive quarter, with optimism running well above average levels; • Inflation and high interest rates have dropped down the CFO risk list;1 • Corporate risk appetite has risen to an 18-month high but remains subdued relative to its long-term average; • 63% of CFOs anticipate higher investment in new technology; • CFOs believe geopolitical factors pose the greatest external risk to their own businesses over the next 12 months. CFOs of the UK’s largest firms are optimistic about prospects for their own businesses as they enter 2024,…

CAMBRIDGE, UK & BOSTON, US – JANUARY 2, 2024 – Apollo Therapeutics (“Apollo” or “the Company”), a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, today announces that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5 million and bringing the total raised in this round by the Company during 2023 to $260 million. “We are delighted to have completed the second close of our Series C financing in December and thank existing investors for their…

ARECOR ANNOUNCES EXPANSION OF EXISTING SPECIALTY HOSPITAL FORMULATION COLLABORATION Cambridge, UK, 8 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces the expansion of its ongoing, exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs. The collaboration, in which Arecor is using its proprietary formulation technology…